Table 1: Open in new tab Patient...

Variables

Controls (n = 102)

IPF (n = 50)

BP carcinoids (n = 99)

ADC (n = 41)

SQC (n = 37)

LCNEC (n = 7)

SCLC (n = 16)

Age (years), median (range)

49 (22–89)

65 (32–85)

59 (20–82)

64 (36–79)

65 (41–82)

70 (56–77)

64 (32–79)

Gender (male:female)

29:73

35:15

36:63

26:15

24:13

4:3

10:6

Tumour histological type/T stage (TNM classification for lung tumours), n %

N/A

TC: 62 (62)
T1: 50 (80)
T2: 8 (13)
T3: 1 (2)
T4: 3 (5)
AC: 37 (37)
T1: 9 (24)
T2: 12 (32)
T3: 12 (32)
T4: 4 (12)

T1: 10 (24)
T2: 16 (39)
T3: 7 (17)
T4: 8 (20)

T1: 2 (5)
T2: 7 (19)
T3: 12 (32)
T4: 16 (44)

T1: 1 (14)
T2: 6 (86)
T3: 0 (0)
T4: 0 (0)

T1: 0 (0)
T2: 1 (6)
T3: 8 (50)
T4: 7 (44)

Disease extent (metastases status), n %

N/A

Advanced metastatic disease (distant metastases): 29 (29)
TC-M1: 12 (20)
AC-M1: 17 (46)

Advanced metastatic disease (distant metastases): 27 (66)

Advanced metastatic disease (distant metastases): 31 (84)

Advanced metastatic disease (distant metastases): 3 (43)

Advanced metastatic disease (distant metastases): 13 (81)

Disease status (RECIST 1.1), n %

N/A

SD: 52 (52)
PD: 47 (47)

SD: 14 (34)
PD: 27 (66)

SD: 14 (38)
PD: 23 (62)

SD: 2 (29)
PD: 5 (61)

SD: 6 (37)
PD: 10 (63)

Current treatment, n %

N/A

Presurgery: 31 (31)
PRRT: 3 (3)
SSA: 22 (22)
Currently not treated: 43 (43)

Presurgery: 13 (32)
Prechemotherapy: 8 (20)
Chemotherapy:^a 14 (34)
Currently not treated: 6 (14)

Presurgery: 2 (5)
Prechemotherapy: 5 (13)
Chemotherapy:^a 16 (44)
Radiation: 4 (11)
Currently not treated: 10 (27)

Presurgery: 5 (61)
CapTEM: 2 (29)

Chemotherapy: 10 (63)^a
Currently not treated: 6 (37)

Table 1:

Open in new tab

Patient demographics

Variables	Controls (n = 102)	IPF (n = 50)	BP carcinoids (n = 99)	ADC (n = 41)	SQC (n = 37)	LCNEC (n = 7)	SCLC (n = 16)
Age (years), median (range)	49 (22–89)	65 (32–85)	59 (20–82)	64 (36–79)	65 (41–82)	70 (56–77)	64 (32–79)
Gender (male:female)	29:73	35:15	36:63	26:15	24:13	4:3	10:6
Tumour histological type/T stage (TNM classification for lung tumours), n %	N/A	N/A	TC: 62 (62) T1: 50 (80) T2: 8 (13) T3: 1 (2) T4: 3 (5) AC: 37 (37) T1: 9 (24) T2: 12 (32) T3: 12 (32) T4: 4 (12)	T1: 10 (24) T2: 16 (39) T3: 7 (17) T4: 8 (20)	T1: 2 (5) T2: 7 (19) T3: 12 (32) T4: 16 (44)	T1: 1 (14) T2: 6 (86) T3: 0 (0) T4: 0 (0)	T1: 0 (0) T2: 1 (6) T3: 8 (50) T4: 7 (44)
Disease extent (metastases status), n %	N/A	N/A	Advanced metastatic disease (distant metastases): 29 (29) TC-M1: 12 (20) AC-M1: 17 (46)	Advanced metastatic disease (distant metastases): 27 (66)	Advanced metastatic disease (distant metastases): 31 (84)	Advanced metastatic disease (distant metastases): 3 (43)	Advanced metastatic disease (distant metastases): 13 (81)
Disease status (RECIST 1.1), n %	N/A	N/A	SD: 52 (52) PD: 47 (47)	SD: 14 (34) PD: 27 (66)	SD: 14 (38) PD: 23 (62)	SD: 2 (29) PD: 5 (61)	SD: 6 (37) PD: 10 (63)
Current treatment, n %	N/A	N/A	Presurgery: 31 (31) PRRT: 3 (3) SSA: 22 (22) Currently not treated: 43 (43)	Presurgery: 13 (32) Prechemotherapy: 8 (20) Chemotherapy:^a 14 (34) Currently not treated: 6 (14)	Presurgery: 2 (5) Prechemotherapy: 5 (13) Chemotherapy:^a 16 (44) Radiation: 4 (11) Currently not treated: 10 (27)	Presurgery: 5 (61) CapTEM: 2 (29)	Chemotherapy: 10 (63)^a Currently not treated: 6 (37)

Variables	Controls (n = 102)	IPF (n = 50)	BP carcinoids (n = 99)	ADC (n = 41)	SQC (n = 37)	LCNEC (n = 7)	SCLC (n = 16)
Age (years), median (range)	49 (22–89)	65 (32–85)	59 (20–82)	64 (36–79)	65 (41–82)	70 (56–77)	64 (32–79)
Gender (male:female)	29:73	35:15	36:63	26:15	24:13	4:3	10:6
Tumour histological type/T stage (TNM classification for lung tumours), n %	N/A	N/A	TC: 62 (62) T1: 50 (80) T2: 8 (13) T3: 1 (2) T4: 3 (5) AC: 37 (37) T1: 9 (24) T2: 12 (32) T3: 12 (32) T4: 4 (12)	T1: 10 (24) T2: 16 (39) T3: 7 (17) T4: 8 (20)	T1: 2 (5) T2: 7 (19) T3: 12 (32) T4: 16 (44)	T1: 1 (14) T2: 6 (86) T3: 0 (0) T4: 0 (0)	T1: 0 (0) T2: 1 (6) T3: 8 (50) T4: 7 (44)
Disease extent (metastases status), n %	N/A	N/A	Advanced metastatic disease (distant metastases): 29 (29) TC-M1: 12 (20) AC-M1: 17 (46)	Advanced metastatic disease (distant metastases): 27 (66)	Advanced metastatic disease (distant metastases): 31 (84)	Advanced metastatic disease (distant metastases): 3 (43)	Advanced metastatic disease (distant metastases): 13 (81)
Disease status (RECIST 1.1), n %	N/A	N/A	SD: 52 (52) PD: 47 (47)	SD: 14 (34) PD: 27 (66)	SD: 14 (38) PD: 23 (62)	SD: 2 (29) PD: 5 (61)	SD: 6 (37) PD: 10 (63)
Current treatment, n %	N/A	N/A	Presurgery: 31 (31) PRRT: 3 (3) SSA: 22 (22) Currently not treated: 43 (43)	Presurgery: 13 (32) Prechemotherapy: 8 (20) Chemotherapy:^a 14 (34) Currently not treated: 6 (14)	Presurgery: 2 (5) Prechemotherapy: 5 (13) Chemotherapy:^a 16 (44) Radiation: 4 (11) Currently not treated: 10 (27)	Presurgery: 5 (61) CapTEM: 2 (29)	Chemotherapy: 10 (63)^a Currently not treated: 6 (37)

Cisplatinum-based therapy (with or without vinorelbine or etoposide).

AC: atypical carcinoid; ADC: adenocarcinoma; BP: bronchopulmonary; CapTEM: capecitabine and temozolomide; IPF: idiopathic pulmonary fibrosis; LCNEC: large-cell neuroendocrine carcinoma; N/A: not applicable; PD: progressive disease; PRRT: peptide receptor radionuclide therapy; RECIST: Response Evaluation Criteria in Solid Tumors; SQC: squamous cell carcinoma; SCLC: small-cell lung cancer; SD: stable disease; SSA: somatostatin analogue; TC: typical carcinoid; TNM: tumour/node/metastasis.

This Feature Is Available To Subscribers Only